In vivo effect of α1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 852-856

  Sadler, B M ^a   Gillotin, C ^a   Lou, Y ^a   Stein, D S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 GLYCOPROTEIN; AMPRENAVIR; PLASMA PROTEIN; PROTEINASE INHIBITOR;

ADULT; AGE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CARBAMATES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OROSOMUCOID; SULFONAMIDES;

EID: 0035115820     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.852-856.2001     Document Type: Article

References (15)

1. Alterations in drug distribution and clearance due to obesity
2. 1 acid glycoprotein
3. Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection
4. Plasma protein binding and erythrocyte partitioning studies in rats, dogs, and humans with the HIV-1 protease inhibitor, 141W94 (VX-478)
5. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
6. Drug binding to human alpha-1-acid glycoprotein in health and disease
7. Influence of race or ethnicity on pharmacokinetics of drugs
8. Effects of age on the protein binding and disposition of propranolol stereoisomers
9. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
10. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
11. 1-Acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV)
12. Plasma protein binding displacement interactions - Why are they still regarded as clinically important?
13. Safety and pharmacokinetics of amprenavir (141W94), an human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
14. A pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
15. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors